Skip to main content
PharmaSGP Holding SE logo

PharmaSGP Holding SE — Investor Relations & Filings

Ticker · PSG ISIN · DE000A2P4LJ5 LEI · 3912005CZ12PVVCIPT91 F Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2023-07-20 Declaration of Voting R…
Country DE Germany
Listing F PSG

About PharmaSGP Holding SE

https://pharmasgp.com/english/

PharmaSGP Holding SE is a pharmaceutical company specializing in the development and marketing of a broad portfolio of over-the-counter (OTC) drugs and other healthcare products. The company focuses on pharmacy-exclusive products for chronic indications, primarily utilizing natural active ingredients with a favorable side-effect profile. It holds a market-leading position in several therapeutic areas, particularly in systemic, chemical-free pain remedies with its RubaXX® (rheumatic pain) and Restaxil® (nerve pain) brand families. The portfolio also includes prominent brands such as Baldriparan® (natural sleep aid), Formigran® (migraine), Spalt® (general pain), and DESEO® and NERADIN® (sexual weakness).

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in the percentage of voting rights held by a specific entity ('Union Investment Privatfonds GmbH') in PharmaSGP Holding SE, referencing German Securities Trading Act (WpHG) sections (Article 40, Sec. 1, Sec. 33, 34, 38). This content directly corresponds to the definition of a notification of changes in significant share ownership levels crossing thresholds, which aligns best with the Major Shareholding Notification (MRQ) category. Although the header mentions 'Voting Rights Announcements', the content is a specific regulatory filing about shareholding changes, not the general results of a vote (DVA).
2023-07-20 English
completes Share Buy-Back Program
Transaction in Own Shares Classification · 100% confidence The document is titled 'PharmaSGP Holding SE completes Share Buy-Back Program' and explicitly states it is a 'Final Reporting for Share Buy-Back Program' under MAR regulation. It details the number of shares bought back, the total purchase price, and provides a day-by-day transaction log for the period January 4, 2023, to July 3, 2023. This content directly relates to the company repurchasing its own shares. According to the definitions, 'Transaction in Own Shares (Code: POS)' covers 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. Although it is a final report, the core subject matter is the share repurchase activity, making POS the most specific classification.
2023-07-10 English
Release of a capital market information
Transaction in Own Shares Classification · 100% confidence The document is titled 'PharmaSGP Holding SE: Release of a capital market information' and explicitly details the company's share buyback activities for July 3, 2023, referencing EU regulations (MAR and Delegated Regulation (EU) No 2016/1052) concerning transactions in own shares. The content focuses entirely on the aggregate volume and weighted average price of shares bought back under a program. This directly corresponds to the definition of 'Transaction in Own Shares' (POS). Although it is a regulatory disclosure, POS is more specific than the general RNS category.
2023-07-10 English
Release of a capital market information
Transaction in Own Shares Classification · 100% confidence The document explicitly details the volume and weighted average price of shares bought back by PharmaSGP Holding SE during a specific period (June 26, 2023, to June 30, 2023) under a share buyback program. This activity falls directly under the definition of a company repurchasing its own shares. The filing category corresponding to this activity is 'Transaction in Own Shares' (POS). Although it is disseminated via EQS News, the core content is the transaction report itself, not just an announcement of a report's publication.
2023-07-03 English
PharmaSGP Holding SE: Strong support at 2023 AGM for very successful business development
AGM Information Classification · 98% confidence The document explicitly mentions '2023 AGM' (Annual General Meeting) multiple times in the title and body, discusses shareholder votes, dividend approval, and reports on the business development discussed at the meeting. The keyword 'AGM/EGM' is present in the metadata section. This strongly indicates the document is related to the Annual General Meeting proceedings or results. Since it summarizes the outcomes and approvals rather than being a presentation (IP) or a formal voting result declaration (DVA), the most appropriate classification is AGM Information (AGM-R). The document length is substantial (6787 chars), suggesting it is more than just a brief announcement of a report (RPA/RNS).
2023-06-29 English
Release of a capital market information
Transaction in Own Shares Classification · 100% confidence The document explicitly details the volume and weighted average price of shares bought back by PharmaSGP Holding SE during a specific period (June 19, 2023, to June 23, 2023), referencing EU regulations (MAR) concerning share buyback programs. This activity—the company purchasing its own stock—directly corresponds to the definition of 'Transaction in Own Shares'. Therefore, the appropriate filing type code is POS.
2023-06-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.